GYRE THERAPEUTICS, INC. quarterly report, Q1 FY2018

Business context and reporting period

Filing identity discrepancy: The request identifies Gyre Therapeutics, Inc., but the supplied Form 10-Q is for Catalyst Biosciences, Inc. (now described in the filing as a clinical-stage biotechnology company). Verify the issuer before relying on this summary. The filing covers the unaudited quarter ended March 31, 2018, compared with the three months ended March 31, 2017.

Catalyst focused on developing treatments for hemophilia and other conditions. Its leading programs were MarzAA, in a Phase 2/3 study, and CB 2679d/ISU 304, a Factor IX candidate; the company had no commercial product sales.

Financial performance and liquidity

The company reported no commercial-product gross margin; the filing does not provide a meaningful operating margin measure. At March 31, 2018, cash and cash equivalents were $126.550 million, short-term investments were $16.968 million, and restricted cash was $175,000. Cash, cash equivalents, and short-term investments totaled about $143.5 million. Total liabilities were $3.035 million and stockholders’ equity was $142.851 million. Redeemable convertible notes were fully repaid or converted at maturity in February 2018; none remained outstanding at quarter-end.

Cash provided by investing activities was $803,000, largely reflecting investment maturities net of purchases. Financing activities provided $111.224 million, primarily from the February equity offering ($106.8 million net) and warrant exercises ($9.5 million), partly offset by approximately $5.1 million of note repayments.

Material changes versus the prior comparable period

• R&D expense rose 83% to $3.771 million, mainly due to MarzAA manufacturing costs, personnel, and preclinical research. Management expected further R&D increases as Catalyst assumed more CB 2679d/ISU 304 development costs.
• G&A expense increased 22% to $2.914 million, primarily from personnel-related costs.
• Revenue declined to $6,000 as the ISU Abxis collaboration performance period concluded in February 2018; no related deferred revenue remained at quarter-end.
• Net loss increased by $904,000, but was partly offset by $1.637 million of interest and other income. This included a $1.5 million milestone payment tied to neuronal nicotinic receptor assets sold in 2016, so reported loss does not reflect operating costs alone.
• The February 2018 public offering and warrant exercises substantially increased cash and common shares. Common shares outstanding rose from 6,081,230 at December 31, 2017 to 11,935,081 at March 31, 2018.
• ASC 606 adoption resulted in a $207,000 cumulative adjustment to opening accumulated deficit. The company also adopted restricted-cash cash-flow reporting guidance, which changed the presentation of prior-year cash flows.

Outlook, risks, contingencies, and unusual items

• Management believed available cash, cash equivalents, and short-term investments would fund projected requirements for at least 12 months from the filing date. It cautioned that assumptions could prove incorrect and additional financing might not be available on acceptable terms.
• Management expected to continue incurring significant expenses and operating losses for at least several years. If financing prospects weaken, the company could delay, reduce, or discontinue programs.
• MarzAA interim data were expected in the second half of 2018. Catalyst reported positive CB 2679d/ISU 304 Phase 1/2 results and said South Korean regulators approved an additional cohort in April 2018; these are clinical updates, not evidence of approval or commercial success.
• The company paid Pfizer a $1 million milestone after the first patient was dosed in the MarzAA Phase 2 study. Potential future Pfizer milestones total up to $17.5 million, plus a single-digit royalty on covered-product sales if commercialized.
• Remaining AGC manufacturing obligations were reported at $6.2 million, subject to completion of work stages. Fixed contractual obligations, including leases, totaled $8.7 million. Potential ISU Abxis milestones of up to $2.0 million were excluded because timing and achievement were uncertain.
• Clinical, regulatory, manufacturing, financing, dilution, and commercialization risks remain significant. The filing reported no material legal proceedings, no off-balance-sheet arrangements, and no material change to previously disclosed risk factors.

Important facts for investors to verify

• Confirm whether this Catalyst Biosciences filing is the intended filing for the requested Gyre Therapeutics summary.
• Check subsequent filings for cash runway, operating burn, financing needs, and share-count changes after the February offering.
• Verify later clinical-trial results and development plans for MarzAA and CB 2679d/ISU 304, including safety, efficacy, and regulatory status.
• Assess the sustainability and accounting treatment of milestone and other non-operating income, and the impact of ASC 606 judgments on collaboration revenue.
• Track outstanding manufacturing commitments and contingent Pfizer and ISU Abxis milestone or royalty obligations.